RotaTeq

Prevention of rotavirus gastroenteritis (caused by serotypes G1, G2, G3, G4, G9) in infants & childn.

Vaccination series: 3 oral doses. Administer 1st dose at 6-12 wk of age & subsequent doses at 4- to 10-wk intervals. Do not administer 3rd dose after 32 wk of age. May be administered to pre-term infants according to their chronological age.

May be taken with or without food: Gently squeeze liqd into infant's mouth towards inner cheek until dosing tube is empty.

Hypersensitivity. Individuals who develop symptoms suggestive of hypersensitivity after receiving a RotaTeq dose. Individuals w/ severe combined immunodeficiency disease.

Not for inj. Replacement dose is not recommended if an incomplete dose is administered. Do not mix w/ any other vaccines or soln. No safety or efficacy data are available in immunocompromised patients eg, individuals w/ malignancies or who are otherwise immunocompromised, & those receiving immunosuppressive therapy; HIV-infected individuals; individuals who have received blood transfusion or blood products, including Ig w/in 42 days. Risk of transmission of vaccine virus strains to non-vaccinated contacts. Administer w/ caution in individuals w/ immunodeficient close contacts; infants w/ active GI illness, chronic diarrhea or growth retardation, or history of congenital abdominal disorders or intussusception. Delay use in case of any acute infection or febrile illness. No clinical data are available when administered after exposure to rotavirus. Not indicated for use in adults. Safety & efficacy have not been established in infants <6 wk of age.

Diarrhea, vomiting; pyrexia.

Vaccines, Antisera & Immunologicals

J07BH02 - rota virus, pentavalent, live, reassorted ; Belongs to the class of rota virus diarrhea vaccines.

P₁S₁S₃